g5-7

JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study

AMG 579 is an efficacious and selective inhibitor of PDE10A (IC50 = 0.1 nM).

Butixirate is a biochemical.

G-573 is an allosteric inhibitor of MEK that is both potent and selective. The IC(50) value for pERK inhibition in HCT116 tumours by G-573 was estimated to be 0.406  µM. The IC(50) values for tumour growth inhibition in HCT116 and H2122 were estimated to be 3.43 and 2.56 µM, respectively. ED(50) estimates in HCT116 and H2122 mouse xenograft models were estimated to be ~4.6 and 1.9 mg/kg/day, respectively.

Rozibafusp alfa is an IgG2-κ antibody targeting ICOSLG, combined with a TNFSF13B fusion protein [1].

G-5758 is an orally active IRE1α inhibitor with an IC50 of 38 nM for XBP1s. It is used in studies involving multiple myeloma models [KMS-11], demonstrating good tolerance in rats at oral doses up to 500 mg/kg. G-5758 exhibits pharmacodynamic effects comparable to those induced by IRE1 knockdown.

MAGL-IN-4 (His121 ARG57) is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.